Volume 22 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(9): 1628-1630
YANG Yunjiao, WANG Xi, YAN Xuelian, XIE Haiyan. Hypothyroidism caused by roxadustat: a case report[J]. Chinese Journal of General Practice, 2024, 22(9): 1628-1630. doi: 10.16766/j.cnki.issn.1674-4152.003698
Citation: YANG Yunjiao, WANG Xi, YAN Xuelian, XIE Haiyan. Hypothyroidism caused by roxadustat: a case report[J]. Chinese Journal of General Practice, 2024, 22(9): 1628-1630. doi: 10.16766/j.cnki.issn.1674-4152.003698
shu

Hypothyroidism caused by roxadustat: a case report

doi: 10.16766/j.cnki.issn.1674-4152.003698
  • 1.

    Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China

Funds:

 ZC201904826

  • Received Date: 2024-02-11
    Abstract
  • This article reports a case of hypothyroidism caused by roxadustat, a prolyl-hydroxylase inhibitor, used to treat renal anemia. An 86-year-old male with a 10-year history of chronic renal insufficiency with reduced speech and food intake for 3 weeks. After 4 months of medication, symptoms of hypothyroidism and abnormal laboratory tests appeared. After discontinuing roxadustat for one week, his thyroid function gradually normalized. For patients receiving roxadustat treatment, regular thyroid function monitoring is essential, and discontinuation or thyroid hormone replacement therapy should be considered if necessary.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    吕晴, 陈卫东, 刘磊. 维持性血液透析患者肾性贫血的多因素分析及相关性研究[J]. 中华全科医学, 2021, 19(5): 871-874. doi: 10.16766/j.cnki.issn.1674-4152.001938

    LYU Q, CHEN W D, LIU L. Multivariate analysis and correlation study of anaemia in patients with maintenance haemodialysis[J]. Chinese Journal of General Practice, 2021, 19(5): 871-874. doi: 10.16766/j.cnki.issn.1674-4152.001938
    [2]
    ICARDI A, PAOLETTI E, DE NICOLA L, et al. Renal anaemia and EPO hypo-responsiveness associated with vitamin D deficiency: the potential role of inflammation[J]. Nephrol Dial Transplant, 2013, 28(7): 1672-1679. doi: 10.1093/ndt/gft021
    [3]
    DROZDZ M, WEIGERT A, SILVA F, et al. Achievement of renal anemia KDIGO targets by two different clinical strategies: a European hemodialysis multicenter analysis[J]. BMC Nephrol, 2019, 20(1): 5. doi: 10.1186/s12882-018-1196-7
    [4]
    MIMA A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages[J]. Eur J Pharmacol, 2021, 912: 174583. DOI: 10.1016/j.ejphar.2021.174583.
    [5]
    HARLOW C E, GANDAWIJAYA J, BAMFORD R A, et al. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies[J]. Am J Hum Genet, 2022, 109(9): 1638-1652. doi: 10.1016/j.ajhg.2022.08.004
    [6]
    CHEN N, HAO C, PENG X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi: 10.1056/NEJMoa1813599
    [7]
    ZHANG L, HOU J, LI J, et al. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis[J]. Aging (Albany NY), 2021, 13(13): 17914-17929.
    [8]
    CHEN N, HAO C, LIU B C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713
    [9]
    LI J, HAASE V H, HAO C M. Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia[J]. Kidney Dis (Basel), 2023, 9(1): 1-11. doi: 10.1159/000527835
    [10]
    ZHENG X, JIN Y, XU T, et al. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study[J]. Ren Fail, 2023, 45(1): 2199093. DOI: 10.1080/0886022X.2023.2199093.
    [11]
    ICHII M, MORI K, MIYAOKA D, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis[J]. BMC Nephrol, 2021, 22(1): 104. doi: 10.1186/s12882-021-02304-2
    [12]
    TOKUYAMA A, KADOYA H, OBATA A, et al. Roxadustat and thyroid-stimulating hormone suppression[J]. Clin Kidney J, 2021, 14(5): 1472-1474. doi: 10.1093/ckj/sfab007
    [13]
    HARAGUCHI T, HAMAMOTO Y, KUWATA H, et al. Effect of roxadustat on thyroid function in patients with renal anemia[J]. J Clin Endocrinol Metab, 2023, 109(1): e69-e75. doi: 10.1210/clinem/dgad483
    [14]
    YAO B, WEI Y, ZHANG S, et al. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance[J]. iScience, 2019, 20: 489-496. doi: 10.1016/j.isci.2019.10.002
    [15]
    VARGHESE T, REJJSH K V, ANAND G, et al. Dietary GABA enhances hypoxia tolerance of a bottom-dwelling carp, Cirrhinus mrigala by modulating HIF-1alpha, thyroid hormones and metabolic responses[J]. Fish Physiol Biochem, 2020, 46(1): 199-212. doi: 10.1007/s10695-019-00708-4
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (25) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return